Gibson Dunn Advised Merck on $9.2 Billion Acquisition of Cidara Therapeutics

Gibson Dunn Advised Merck on $9.2 Billion Acquisition of Cidara Therapeutics

The Global Law firm, Gibson Dunn advised Merck in connection with its $9.2 billion acquisition of Cidara Therapeutics, Inc., a biotechnology company developing drug-Fc conjugate (DFC) therapeutics.

The Gibson Dunn transaction team was led by Saee Muzumdar (Partner) and included Sebastian Fain (Partner), Tracey Tomlinson (Associate), and Kira Dennis (Associate). The team also advised on tax, benefits, life sciences, IP, antitrust, and FDA-related matters, including Pamela Lawrence Endreny (Partner, Tax), Michael Collins (Partner, Benefits), Karen Spindler (Partner, Life Sciences), Meghan Hungate (Partner, IP), Jacqueline Malzone (Associate, IP), Mona Mosavi (Associate, IP), Steve Weissman (Partner, Antitrust), Bradley Smith (Partner, Antitrust), Caroline Black (Associate, Antitrust), and Katlin McKelvie (Partner, FDA-related matters).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.